Local recurrence after ductal carcinoma in situ breast conserving treatment. Analysis of 195 cases

Cutuli, B.; Lemanski, C.; Blanc-Onfroy, M. Le; Lafontan, B. De; Cohen-Solal-Le-Nir, C.; Fondrinier, É.; Mignotte, H.; Giard, S.; Charra-Brunaud, C.; Auvray, H.; Gonzague-Casabianca, L.; Quétin, Philippe; Fay, Renaud

doi:10.1016/j.canrad.2013.01.011

Cited by 20 publications

(8 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rate of radiotherapy (RT) after BCS was higher in US hospital than that in our center during the same time period. The local recurrence rates of patients with DCIS were 2.1% or 30.1% after the treatment of mastectomy or BCS in the reports of Cutuli et al [21]. However, in our study, the patients with local recurrence were found in 9.1% in the BCS, which is similar to 7.7% in the BCS in the report of the Ozkan-Glrudal study [16].…”

Section: Discussionsupporting

confidence: 79%

The clinical features and management of women with ductal carcinoma in situ with microinvasion: A retrospective Cohort study

Zhang

Wei

et al. 2015

International Journal of Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 79%

The clinical features and management of women with ductal carcinoma in situ with microinvasion: A retrospective Cohort study

Zhang

Wei

et al. 2015

International Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…This is a crucial problem, because now several studies confirm the unfavourable impact of invasive LR in patients treated for DCIS with a 12-18% long-term of metastatic evolution [ 21 , 22 , 32 ]. For LCIS, there are no clear therapeutic guidelines, both after CNB and surgical excision [ 1 , 2 , 9 ].…”

Section: Discussionmentioning

confidence: 99%

Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases

et al. 2015

View full text Add to dashboard Cite

BackgroundLobular carcinomas in situ (LCIS) represent 1-2% of all breast cancers. Both significance and treatment remain widely debated, as well as the possible similarities with DCIS.Materials and methodsTwo hundred patients with pure LCIS were retrospectively analyzed in seven centres from 1990 to 2008. Median age was 52 years; 176 patients underwent breast-conserving surgery (BCS) and 24 mastectomy. Seventeen patients received whole breast irradiation (WBRT) after BCS and 20 hormonal treatment (15 by tamoxifen).ResultsWith a 144-month median follow-up (FU), there were no local recurrences (LR) among 24 patients treated by mastectomy. With the same FU, 3 late LR out of 17 (17%) occurred in patients treated by BCS and WBRT (with no LR at 10 years). Among 159 patients treated by BCS alone, 20 developed LR (13%), but with only a 72-month FU (17.5% at 10 years). No specific LR risk factors were identified. Three patients developed metastases, two after invasive LR; 22 patients (11%) developed contralateral BC (59% invasive) and another five had second cancer.ConclusionsLCIS is not always an indolent disease. The long-term outcome is quite similar to most ductal carcinomas in situ (DCIS). The main problems are the accuracy of pathological definition and a clear identification of more aggressive subtypes, in order to avoid further invasive LR. BCS + WBRT should be discussed in some selected cases, and the long-term results seem comparable to DCIS.

show abstract

“…3 Prognosis is favorable in most cases, but invasive local recurrences (LRs) can lead to metastasis in 10% to 15% of cases. [4][5][6][7] The treatment modalities for DCIS have been widely debated for many years, with several major questions concerning the role of mastectomy, sentinel node biopsy (SNB), whole breast radiotherapy (RT) with or without boost after breast-conserving surgery (BCS), and the real impact of tamoxifen. [8][9][10] In order to analyze real-life clinical practice, a first national prospective survey was performed in France from March 2003 to April 2004 to assess the epidemiologic data, diagnosis, and treatment modalities in 1289 patients with pure DCIS.…”

Section: Introductionmentioning

confidence: 99%

Ductal Carcinoma in Situ: A French National Survey. Analysis of 2125 Patients

Cutuli

Lemanski

Lafontan

et al. 2020

Clinical Breast Cancer

View full text Add to dashboard Cite

This was an analysis of 2125 ductal carcinoma in situ features/treatments from 71 French centers. Mastectomy and breast-conserving surgery was performed in 25% and 75% of cases, respectively; the median tumor size was 15 mm, and the low, intermediate, and high nuclear grade distribution was 12%, 36%, and 47%, respectively. After breast-conserving surgery, 97% underwent whole breast irradiation. This survey reflects the daily ductal carcinoma in situ treatment in France, and the results are in accordance with national guidelines. Background: Ductal carcinoma in situ (DCIS) represents 15% of all breast cancers in France. The first national survey was conducted in 2003. The present multi-center real-life practice survey aimed at assessing possible changes in demographic, clinical, pathologic, and treatment features. Material and Methods: From March 2014 to September 2015, patients diagnosed with DCIS from 71 centers with complete information about age, diagnostic features, and treatment modalities were prospectively included. Results: A total of 2125 patients with a median age of 58.6 years from 71 centers were studied. DCIS was diagnosed by mammography in 87.5% of cases. Preoperative biopsy was performed in 96% of cases. The median tumor size was 15 mm. Nuclear grade was low, intermediate, and high in 12%, 36%, and 47% of cases, respectively. Margins were considered to be negative in 83% of cases. Overall mastectomy and lumpectomy rates were 25% and 75%, respectively. The immediate breast reconstruction rate was 50%. Sentinel node biopsy and axillary dissection rates were 41% and 2.6%, respectively. After lumpectomy, 97% of patients underwent radiotherapy, and 32% received a boost dose. Only 1% of patients received endocrine therapy. Compared with our previous survey, the median tumor size remained the same, and the proportion of high-grade lesions increased by 9%. The mastectomy rate decreased by 4%. Conclusions: The clinical practice identified in this survey complies with French DCIS guidelines. About 10% of patients with low-grade DCIS may be eligible to participate in treatment de-escalation trials.

show abstract

Local recurrence after ductal carcinoma in situ breast conserving treatment. Analysis of 195 cases

Cited by 20 publications

References 62 publications

The clinical features and management of women with ductal carcinoma in situ with microinvasion: A retrospective Cohort study

The clinical features and management of women with ductal carcinoma in situ with microinvasion: A retrospective Cohort study

Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases

Ductal Carcinoma in Situ: A French National Survey. Analysis of 2125 Patients

Contact Info

Product

Resources

About